A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Inclusion Criteria: * Initial diagnosis of metastatic pancreatic cancer must have occurred ≤6 weeks prior to the completion of screening. * The presence of measurable metastatic pancreatic cancer documented by contrast enhanced CT (or MRI) scan in addition to 1 of the following: 1. Histological diagnosis of pancreatic adenocarcinoma confirmed by pathologist OR 2. Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreatic origin in conjunction with either: 1. The presence of a mass in the pancreas OR 2. A history of resected pancreatic carcinoma * Measurable disease per RECIST (ver. 1.1) * ECOG Performance Status of 0 or 1. * Adequate hepatic, hematologic and renal functions. Exclusion Criteria: * A history or evidence of clinically significant disorder other than metastatic cancer of the pancreas. * A diagnosis of pancreatic islet neoplasms. * Subject has undergone major surgery other than diagnosis surgery within 4 weeks of randomization * Presence of biliary obstruction requiring external drainage * Brain metastases. * Unstable cardiovascular function within the last 6 months of screening * Clinically active liver disease, including active viral hepatitis (HBV or HCV) or cirrhosis * Known HIV infection. * Uncontrolled hypertension at Screening * History or presence of any form of cancer, other than pancreatic cancer, within the 3 years prior to enrollment * Prior or concurrent anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) for the treatment of inoperable locally advanced or metastatic pancreatic cancer; prior radiotherapy and chemotherapy given as pre-operative neoadjuvant therapy or radio sensitizers for locally advanced pancreatic cancer are allowed. * Uncontrolled systemic fungal, bacterial or viral infection * Participation in an investigational drug or device trial with therapeutic intent within 30 days prior to study